Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed ductal adenocarcinoma of the pancreas~  * Locally advanced or metastatic disease not amenable to curative surgical resection~ * Macroscopic residual disease after prior resection with histological confirmation is allowed~* Unidimensionally measurable disease~* No intracerebral metastases or meningeal carcinomatosis~PATIENT CHARACTERISTICS:~Age:~* Over 18~Performance status:~* WHO 0-2~Life expectancy:~* More than 3 months~Hematopoietic:~* WBC greater than 3,000/mm3~* Neutrophil count greater than 1,500/mm3~* Platelet count greater than 100,000/mm3~Hepatic:~* Bilirubin less than 2 mg/dL~Renal:~* Creatinine less than 2 mg/dL~* Creatinine clearance greater than 50 mL/min~Cardiovascular:~* No New York Heart Association class III or IV heart disease~* No uncontrolled angina pectoris~Other:~* No other prior malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix~* No other concurrent uncontrolled medical condition~* No other medical or psychiatric condition that would preclude study~* No known hypersensitivity to fluorouracil~* No dihydropyrimidine dehydrogenase deficiency~* No known malabsorption syndromes~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy (including preoperative or adjuvant) for this disease~* No other concurrent cytotoxic chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy (including preoperative or adjuvant) for this disease~Surgery:~* See Disease Characteristics~Other:~* No prior investigational drugs (including preoperative or adjuvant) for this disease~* No other concurrent investigational drugs~* No concurrent dipyridamole or allopurinol~* No concurrent sorivudine or sorivudine analogs (e.g., brivudine) (capecitabine arm only)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).